| 產(chǎn)品編號 | BIO0911SM |
| 英文名稱 | Anti-human TNFSF7 / CD27L / CD70 (Vorsetuzumab mafodotin Biosimilar) |
| 中文名稱 | |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 146.1 kDa |
| 檢測分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | Human IgG1 |
| 純化方法 | Protein A |
| 保存條件 | For long term storage, the produce should be stored at -20°C or lower. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Human TNFSF7 / CD27L / CD70 CHO-K1 Cell Line were stained with Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS,The EC50 is 0.11
μg/mL.
Immobilized humanCD70-His at 2 ug/mL (30 μL/well) can bind Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) with the EC50 of 0.007612 ug/mL.
The drug-to-antibody ratio (DAR) of the Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) is 3.8.
The purity of Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) is 99.29%, determined by SEC-HPLC.
|
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
